Community

Sunzen Biotech Berhad: Q1 FY25 Financial Insights and Technical Outlook Financial Performance Overview Sunzen Biotech Berhad posted a stable financial performance for Q1 FY25, achieving a revenue of RM22.96 million, an 11.42% increase compared to the preceding quarter. Key contributors were: • Human Health Segment: RM17.65 million in revenue, driven by robust export sales of edible bird’s nests to China, constituting 79.32% of segment revenue.

Coupang Inc. (NYSE: CPNG) is a prominent e-commerce company based in South Korea, often referred to as the "Amazon of South Korea." Sector: Technology Industry: e-commerce, Internet Retail, Consumer Cyclical Market Capitalization: 40.0b (mid cap) Major Competitors: Local Competitors in South Korea Naver: Naver is South Korea's largest search engine and one of the biggest competitors to Coupang in the e-commerce space.

Key Takeaways The end of ACP will lead to a short-term revenue decline. Predictive AI is providing more valuable customer service experiences.

Long term price target of $25 Originally published on 3/31/25 in The Millegan Memo https://www.woodworth.fund/news/the-millegan-memo-march-2025 ALL ABOARD THE VALUE TRAIN: WHY $RAIL MIGHT BE HEADED NORTH - FREIGHTCAR AMERICA Freightcar America continues to deliver on operational results. Freightcar America, which despite the name has no actual manufacturing operations in the US, reported its four quarter and full year 2024 earnings results earlier this March.

PayPal exhibits a robust financial position with a substantial cash reserve and consistent profitability. The company's strong balance sheet enables investments in growth initiatives, irrespective of the prevailing economic conditions.

Intrinsic Value per Share (DCF-based): Rs. 40.00 Current Market Price (CMP): Rs. 80.00 ⚠️ Overvaluation: CMP is 100% above intrinsic value! Key Concerns and Valuation Risks Overpriced Relative to Intrinsic Value Even under an optimistic growth scenario (10% FCF growth), the stock’s intrinsic value only reaches Rs. 57.

Catalysts Most Immediate Catalysts (1–2 Years) Resilient Demand for Life Sciences & Diagnostics – TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles. Cost Synergies from PPD Acquisition – The 2021 acquisition of PPD (clinical research services) is expected to enhance revenue synergies and margin expansion.

Catalysts Membership Growth : MOH has seen a 9% increase in members year over year, reaching approximately 5.7 million members as of March 31, 2024. This growth is driven by new contract wins, acquisitions, and expansion.

Management guidance (FY2025 Q2) -- $23 - $25bn revenue guidance for 2025, and positive about reaching $40bn in revenue for 2026, this is due to the DLC technology (Direct Liquid Cooling) that is expected to be adopted by an estimate of 30% of the new data center space. New Auditor & Special Committee -- After almost a 85% decline in share price after Hidenburg's (short seller) accounting manipulation report on the company, SMCI' has already increased their stock price in more than 200% expecting to release all of their adjusted and revised filings for FY2024 (10-K) and the first two quarters of 2025 (10-Q).